Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
To measure the effect of Teriflunomide on lymphocytes subsets in patients with relapsing
forms of multiple sclerosis as compared with baseline values and those of a reference
population of untreated healthy subjects.
Secondary Objectives:
To assess if Teriflunomide treatment results in biased T cell clonal diversity. To assess the
effect of Teriflunomide on the function of peripheral blood mononuclear cells (proliferation
and cytokine production in situ).
To assess the circulating cytokines profile in the serum of Relapsing Multiple Sclerosis
(RMS) patients during a 24-week treatment versus baseline and healthy controls.
To assess the reversibility of all parameter changes in patients who discontinue treatment
after accelerated elimination procedure with cholestyramine or activated charcoal.